Palisade Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Palisade Bio (PALI).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$10Upside to Avg. PT+551.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Raymond James	Thomas Deal	Initiate	Outperform	$6
Sep 23, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$7
Jul 23, 2026	Oppenheimer	Leland Gershell	Initiate	Outperform	$8
Apr 9, 2026	Wolfe Research	Andy Chen	Initiate	Outperform	$7
Mar 26, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$7
Feb 25, 2026	Stifel	Alex Thompson	Initiate	Buy	$5
Jan 9, 2026	B. Riley Securities	William Woods	Initiate	Buy	$7
Dec 30, 2025	Clear Street	Kaveri Pohlman	Initiate	Buy	$12
Dec 29, 2025	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$25
May 13, 2025	Brookline Capital	Kumaraguru Raja	Maintained	Buy	$16
Nov 20, 2024	Brookline Capital	Kumaraguru Raja	Initiate	Buy	$38
Nov 13, 2024	Maxim Group	Naz Rahman	PT Cut	Buy	$23→$8
May 1, 2024	Maxim Group	Naz Rahman	Maintained	Buy	$23
Apr 16, 2024	Maxim Group	Naz Rahman	Maintained	Buy	$23
Nov 17, 2023	Maxim Group	Naz Rahman	Upgrade	Hold→Buy	$2

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6

Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.

Benzinga Newsdesk

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.

Vandana Singh

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.

Avi Kapoor

PRO
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.

Benzinga Newsdesk

Palisade Bio Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Palisade Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

PRO
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

People Also Watch

People Also Watch

Palisade Bio Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Palisade Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORaymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6

PROHC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2

This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROOppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

PROWolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

People Also Watch

People Also Watch

PRO
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target

PRO
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8

PRO
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7